Previous 10 | Next 10 |
PTC Therapeutics Provides a Corporate Update and Reports Second Quarter 2021 Financial Results - Total quarterly net revenue of $117 million; 55% increase over second quarter 2020 - - Raises 2021 DMD franchise revenue guidance to $370-$390M from $355-$375M - - Progress a...
Significant Improvements in Survival and Developmental Milestones Demonstrated in Type 1 SMA Patients Treated with Evrysdi™ - Results from Part 2 of FIREFISH pivotal study published in the New England Journal of Medicine - PR Newswire SOUTH PLAINFIELD, N.J. ...
PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2021 Financial Results PR Newswire SOUTH PLAINFIELD, N.J. , July 15, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast confer...
Results Add to Body of Evidence Confirming EMFLAZA®'s Benefit Over Prednisone - Data presented at the 2021 Parent Project Muscular Dystrophy Annual Conference - PR Newswire SOUTH PLAINFIELD, N.J. , June 24, 2021 /PRNewswire/ -- PTC Therapeutics, Inc...
Evrysdi™ Approved in Japan for the Treatment of Spinal Muscular Atrophy - 48th country that approved Evrysdi - - First commercial sale in Japan will trigger $10M milestone payment from Roche - PR Newswire SOUTH PLAINFIELD, N.J. , June 23, 2021 /PRN...
Pre-symptomatic Infants with Spinal Muscular Atrophy Achieved Same Motor Milestones as Healthy Children After Treatment with Evrysdi™ in RAINBOWFISH - JEWELFISH results demonstrated stabilization in motor function in broad SMA population - - Evrysdi has proven efficac...
PTC Therapeutics Announces Orphan Drug Designations of PTC923 for the Treatment of Hyperphenylalaninemia PR Newswire SOUTH PLAINFIELD, N.J. , May 26, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that both the United States Food ...
PTC Therapeutics to Participate at Upcoming Virtual Investor Conference PR Newswire SOUTH PLAINFIELD, N.J. , May 19, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the following confer...
New Data Shows Devastating Impact of AADC Deficiency on Caregivers - Caregivers spend on average 15 hours a day providing care - PR Newswire SOUTH PLAINFIELD, N.J. , May 17, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced data ...
PTC Therapeutics, Inc. (PTCT) Q1 2021 Results Conference Call May 04, 2021 04:30 PM ET Company Participants Kylie O'Keefe - Senior Vice President Commercial and Corporate Strategy Stuart Peltz - Chief Executive Officer Matthew Klein - Chief Development Officer Eric Pauwels - Chief Business Of...
News, Short Squeeze, Breakout and More Instantly...
PTC Therapeutics Inc. Company Name:
PTCT Stock Symbol:
NASDAQ Market:
PTC Therapeutics Inc. Website:
PTC Therapeutics Announces Sepiapterin NDA Submission to FDA PR Newswire WARREN, N.J. , July 30, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the submission of the sepiapterin NDA to the U.S. FDA. The NDA submission is for the t...
PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2024 Financial Results PR Newswire WARREN, N.J. , July 25, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to r...
2024-07-12 10:00:03 ET Jeffrey Hung from Morgan Stanley issued a price target of $32.00 for PTCT on 2024-07-12 08:15:00. The adjusted price target was set to $32.00. At the time of the announcement, PTCT was trading at $33.2. The overall price target consensus is at $43....